• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sandoz Group

News headline image
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
August 12, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
August 07, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
July 30, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
July 01, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
June 02, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
May 21, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
April 30, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
April 29, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 15, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
March 31, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports strong FY 2024 results and Q4 2024 sales
March 05, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
February 24, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Francisco Ballester to retire; Peter Stenico appointed President Region International
February 03, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
December 17, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
November 15, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports third-quarter and nine-month 2024 sales
October 30, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
October 11, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
August 12, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports second-quarter sales and half-year 2024 results
August 08, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
July 25, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports first quarter 2024 sales
May 07, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap